-

Medidata Launches the Site Insights Program to Elevate the Site Voice for Trials

Program supports the Medidata Patient, Data, and Study Experiences, boosting site engagement, eliminating clinical trial inefficiencies, and increasing tech compliance

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that it has introduced its Medidata Site Insights Program, a collection of initiatives to accelerate the delivery of life-changing therapies to patients. The new framework will help promote a more open dialogue with sites, transforming the clinical trial ecosystem, spearheading innovation, and reducing technological burden.

“At the heart of Medidata is the steadfast vision to fundamentally transform the clinical trial ecosystem. Dedicated to eliminating inefficiencies that delay progress, our mission is to cultivate a world-class site experience through direct and open collaboration with these critical stakeholders,” said Robin Douglas, vice president, research site engagement, Medidata. “By including the site voice in our ongoing discussions, we're not just streamlining clinical trial processes and enhancing technology but helping our clients to deliver effective treatments to patients sooner.”

According to WCG's 2023 Clinical Research Site Challenges Report, 47% of sites find it difficult to adopt new technologies and systems. Medidata’s transformative program seeks to address this issue through both existing and new initiatives:

  • Executive Site Advisory Board: A new initiative that encompasses a select group of leading industry executives leveraging their deep therapeutic expertise and access to patient populations to help shape Medidata’s solutions.
  • Site User Community: Medidata established a new dynamic community through Engage, where site users can provide real-time feedback using polls, surveys, and segmented discussions. This direct line of communication allows for Medidata to better align products with the evolving needs and challenges of sites.
  • Site Tech Board: In collaboration with the Society of Clinical Research Sites (SCRS), Medidata will continue to host interactive design studio workshops. These workshops unite site users and Medidata’s product team to optimize new technologies, delivering user-friendly and efficient solutions for all organizations.
  • Strategic Partnerships: Medidata cultivates industry and site collaborations to drive shared objectives. These partnerships enable sites to play an active role in shaping Medidata’s culture and improving the overall clinical trial ecosystem.

To learn more about the Site Insights Program, visit here.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com

Contacts

Medidata PR
Medidata.PR@3ds.com

Analyst Relations
medidata.AR@3ds.com

Medidata

BOURSE:DSY

Release Versions

Contacts

Medidata PR
Medidata.PR@3ds.com

Analyst Relations
medidata.AR@3ds.com

More News From Medidata

ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will immediately begin utilizing Medidata Clinical Data Studio on its studies, differentiating ICON as the first large CRO to fully infuse this technology into its clinical workflows. The integration of Clinical Data Stud...

Medidata Advances New Frontiers for Life Sciences Through Patient-Centric Experiences, AI-Powered Innovations, and New Patient Engaging Alliances

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand, reaffirms its vision and commitment to advancing the life sciences industry and transforming patient experiences across the entire clinical development process, from pre-trial planning, to post-trial outcomes, and ongoing patient care. With advanced technologies, such as AI and virtual twins, Medidata enables biopharmaceutical companies, researchers, and patients to accelerate therapy development and improve patient lives. A truste...

Medidata and Tigermed Renew Strategic Partnership Aimed at Accelerating Clinical Trials Globally

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has extended its 13-year relationship with Tigermed, a leading global provider of clinical research solutions across the full life cycle of global biopharmaceutical and medical device products. This extended partnership will further harness the Medidata Platform from early-phase trials to post-marketing surveillance, to optimize study workflows, ensure r...
Back to Newsroom